Bloom Burton Has Negative Estimate for TSE:MDP Q4 Earnings

Medexus Pharmaceuticals Inc. (TSE:MDP) – Equities research analysts at Bloom Burton cut their Q4 2025 earnings per share (EPS) estimates for Medexus Pharmaceuticals in a research note issued on Thursday, January 23rd. Bloom Burton analyst D. Martin now expects that the company will earn ($0.01) per share for the quarter, down from their previous estimate of $0.01. The consensus estimate for Medexus Pharmaceuticals’ current full-year earnings is $0.16 per share.

Other equities research analysts have also issued research reports about the company. Alliance Global Partners raised Medexus Pharmaceuticals to a “strong-buy” rating in a report on Monday, December 23rd. Raymond James raised shares of Medexus Pharmaceuticals from an “outperform” rating to a “strong-buy” rating and set a C$4.00 price target for the company in a research note on Wednesday, January 8th. Leede Financial upgraded shares of Medexus Pharmaceuticals from a “moderate buy” rating to a “strong-buy” rating in a research report on Wednesday. Stifel Nicolaus increased their target price on shares of Medexus Pharmaceuticals from C$4.15 to C$4.50 in a report on Tuesday, January 14th. Finally, Ventum Cap Mkts upgraded shares of Medexus Pharmaceuticals to a “strong-buy” rating in a research note on Friday, January 17th. One research analyst has rated the stock with a buy rating and five have issued a strong buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Strong Buy” and a consensus target price of C$5.58.

Medexus Pharmaceuticals Price Performance

TSE:MDP opened at C$4.47 on Friday. The company has a market capitalization of C$109.65 million, a P/E ratio of 89.40 and a beta of 1.96. The business has a fifty day simple moving average of C$3.14 and a two-hundred day simple moving average of C$2.69. Medexus Pharmaceuticals has a 1 year low of C$1.47 and a 1 year high of C$5.56.

Medexus Pharmaceuticals Company Profile

Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.